Pulmonary artery catherization and early heart failure medication in cardiogenic shock due to heart failure

Pulmonary artery catheterization and Carverdilol early initiation in cardiogenic shock casued by heart failure with reduced ejection fraction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008681

Enrollment

160

Registered

2023-08-04

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : From the time of diagnosing cardiogenic shock caused by heart failure with reduced ejection fraction within 12 hours, random allocation will be conducted. If assigned to the hemody

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adults age 19 and above ( no age limit for elderly ) 2) Patients with cardiogenic shock requiring intensive care monitoring in ICU 3) Patients elegible for oral medication administration 4) Patients who have provided research participation consent through a written informed consent form

Exclusion criteria

Exclusion criteria: 1) Unwilling or unable to obtain informed consent by the participant or substitute decision maker 2) Patients with acute coronary syndrome 3) Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery 4) Known hypersensitivity to beta-blockers 5) Patients with a history of bronchospasm or asthma 6) Patients with bradycardia or second or third-degree atrioventricular block 7) Patients with sick sinus syndrome, including sinoatrial block 8) Patients with untreated pheochromocytoma 9) Patients currently undergoing de-sensitization therapy 10) Patients who are currently pregnant, postpartum period within 30 days or breast-feeding

Design outcomes

Primary

Measure	Time frame
90-day all-cause mortality	—

Secondary

Measure	Time frame
All-cause mortality and cardiovascular mortality;Timing of discontinuation of inotropic or vasopressor agents;Pulmonary artery catheter monitoring parameters;The rate of Carvedilol intake on the 90th day;The target-dose achievement rate of Carvedilol on the 90th day;Heart failure rehospitalization rate;Follow-up echocardiography parameters;Complications related with pulmonary artery catheter	—

Countries

Korea, Republic of

Contacts

Public ContactAh-Ram Kim

Asan Medical Center

ahram3256@gmail.com+82-2-3010-0111

Outcome results